Beam Therapeutics Q2 EPS $(1.23) Down From $(0.69) YoY
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.23) per share. This is a 78.26 percent decrease over losses of $(0.69) per share from the same period last year.
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
61 Biggest Movers From Yesterday
Gainers
BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs.
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ:BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ:APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will…
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.